S&P 500   4,603.51 (-0.02%)
DOW   36,332.72 (+0.23%)
QQQ   393.09 (+0.23%)
AAPL   191.46 (-2.17%)
MSFT   368.12 (-1.63%)
META   320.46 (-3.69%)
GOOGL   132.06 (-2.17%)
AMZN   144.53 (-1.96%)
TSLA   239.33 (-1.85%)
NVDA   459.39 (-3.30%)
NIO   7.45 (+0.95%)
BABA   71.55 (-0.82%)
AMD   133.09 (+3.23%)
T   16.67 (-1.48%)
F   11.07 (+0.54%)
MU   77.62 (+3.55%)
CGC   0.80 (+0.33%)
GE   120.22 (-0.31%)
DIS   92.55 (-0.29%)
AMC   6.81 (-1.73%)
PFE   28.57 (-0.73%)
PYPL   59.27 (+0.56%)
XOM   99.30 (-0.25%)
S&P 500   4,603.51 (-0.02%)
DOW   36,332.72 (+0.23%)
QQQ   393.09 (+0.23%)
AAPL   191.46 (-2.17%)
MSFT   368.12 (-1.63%)
META   320.46 (-3.69%)
GOOGL   132.06 (-2.17%)
AMZN   144.53 (-1.96%)
TSLA   239.33 (-1.85%)
NVDA   459.39 (-3.30%)
NIO   7.45 (+0.95%)
BABA   71.55 (-0.82%)
AMD   133.09 (+3.23%)
T   16.67 (-1.48%)
F   11.07 (+0.54%)
MU   77.62 (+3.55%)
CGC   0.80 (+0.33%)
GE   120.22 (-0.31%)
DIS   92.55 (-0.29%)
AMC   6.81 (-1.73%)
PFE   28.57 (-0.73%)
PYPL   59.27 (+0.56%)
XOM   99.30 (-0.25%)
S&P 500   4,603.51 (-0.02%)
DOW   36,332.72 (+0.23%)
QQQ   393.09 (+0.23%)
AAPL   191.46 (-2.17%)
MSFT   368.12 (-1.63%)
META   320.46 (-3.69%)
GOOGL   132.06 (-2.17%)
AMZN   144.53 (-1.96%)
TSLA   239.33 (-1.85%)
NVDA   459.39 (-3.30%)
NIO   7.45 (+0.95%)
BABA   71.55 (-0.82%)
AMD   133.09 (+3.23%)
T   16.67 (-1.48%)
F   11.07 (+0.54%)
MU   77.62 (+3.55%)
CGC   0.80 (+0.33%)
GE   120.22 (-0.31%)
DIS   92.55 (-0.29%)
AMC   6.81 (-1.73%)
PFE   28.57 (-0.73%)
PYPL   59.27 (+0.56%)
XOM   99.30 (-0.25%)
S&P 500   4,603.51 (-0.02%)
DOW   36,332.72 (+0.23%)
QQQ   393.09 (+0.23%)
AAPL   191.46 (-2.17%)
MSFT   368.12 (-1.63%)
META   320.46 (-3.69%)
GOOGL   132.06 (-2.17%)
AMZN   144.53 (-1.96%)
TSLA   239.33 (-1.85%)
NVDA   459.39 (-3.30%)
NIO   7.45 (+0.95%)
BABA   71.55 (-0.82%)
AMD   133.09 (+3.23%)
T   16.67 (-1.48%)
F   11.07 (+0.54%)
MU   77.62 (+3.55%)
CGC   0.80 (+0.33%)
GE   120.22 (-0.31%)
DIS   92.55 (-0.29%)
AMC   6.81 (-1.73%)
PFE   28.57 (-0.73%)
PYPL   59.27 (+0.56%)
XOM   99.30 (-0.25%)

Lisata Therapeutics (LSTA) Stock Price, News & Analysis

$2.60
-0.01 (-0.38%)
(As of 10:49 AM ET)
Compare
Today's Range
$2.60
▼
$2.64
50-Day Range
$2.02
▼
$2.61
52-Week Range
$1.95
▼
$4.53
Volume
1,628 shs
Average Volume
19,434 shs
Market Capitalization
$21.16 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.00
Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media

Lisata Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
474.7% Upside
$15.00 Price Target
Short Interest
Healthy
0.70% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.00mentions of Lisata Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.91) to ($2.68) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.19 out of 5 stars

Medical Sector

348th out of 942 stocks

Pharmaceutical Preparations Industry

131st out of 424 stocks

See Top Rated MarketRank™ Stocks Here

LSTA stock logo

About Lisata Therapeutics Stock (NASDAQ:LSTA)

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 1b/2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; HONEDRA, a recipient of SAKIGAKE designation critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and LSTA201, a CD34+ cell therapy for the treatment of chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. The company was formerly known as Caladrius Biosciences, Inc. and changed its name to Lisata Therapeutics, Inc. on September 15, 2022. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.

LSTA Stock Price History

LSTA Stock News Headlines

December 9, 2023 | morningstar.com
Lisata Therapeutics Inc LSTA
December 7, 2023 | americanbankingnews.com
Lisata Therapeutics (NASDAQ:LSTA) Stock Price Up 8.8%
December 11, 2023 | Autonomix (Ad)
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology
Autonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
November 28, 2023 | finance.yahoo.com
Lisata Therapeutics to Present at NobleCon19 Investor Conference
November 9, 2023 | finance.yahoo.com
Lisata Therapeutics Announces Participation in Upcoming Conferences in November
November 7, 2023 | finance.yahoo.com
All You Need to Know About Lisata Therapeutics, Inc. (LSTA) Rating Upgrade to Buy
November 5, 2023 | finance.yahoo.com
Lisata Therapeutics, Inc. (NASDAQ:LSTA) Q3 2023 Earnings Call Transcript
November 3, 2023 | markets.businessinsider.com
Strong Financials and Advancements in Clinical Trials Bolster Buy Rating for Lisata Therapeutics
December 11, 2023 | Autonomix (Ad)
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology
Autonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
November 3, 2023 | finance.yahoo.com
Q3 2023 Lisata Therapeutics Inc Earnings Call
November 2, 2023 | finance.yahoo.com
Lisata Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
November 1, 2023 | benzinga.com
Earnings Preview: Lisata Therapeutics
October 26, 2023 | finance.yahoo.com
Lisata Therapeutics to Host Third Quarter 2023 Financial Results Conference Call on Thursday, November 2nd at 4:30 p.m. Eastern Time
October 24, 2023 | finance.yahoo.com
Lisata Therapeutics Announces First Patient Treated in the Cholangiocarcinoma Cohort of the BOLSTER Trial of LSTA1, a Novel Tumor-Targeting and Penetrating Peptide
October 18, 2023 | msn.com
Lisata's (LSTA) Lead Cancer Drug Gets EC's Orphan Tag, Stock Up
October 17, 2023 | marketwatch.com
Lisata Therapeutics Shares Rise 11% After Cancer Drug LSTA1 Granted Orphan Drug Status in EU
October 17, 2023 | msn.com
Lisata Therapeutics says EMA grants its pancreatic drug treatment orphan drug status
October 17, 2023 | finance.yahoo.com
Lisata Therapeutics Announces European Medicines Agency Has Granted LSTA1 Orphan Drug Designation for the Treatment of Pancreatic Cancer
September 20, 2023 | finance.yahoo.com
Lisata Therapeutics Announces Participation in InfoSec World 2023
September 12, 2023 | finance.yahoo.com
Lisata Therapeutics Announces First Patient Treated in the BOLSTER Trial of LSTA1, a Novel Tumor-Targeting and Penetrating Peptide, in Patients with Advanced Solid Tumors
September 6, 2023 | finance.yahoo.com
Lisata Therapeutics Announces Outcome of Interim Futility Analysis for its Phase 2b ASCEND Trial of LSTA1 in Metastatic Pancreatic Ductal Adenocarcinoma
September 5, 2023 | finance.yahoo.com
Lisata Therapeutics Announces Participation in Upcoming Conferences in September
August 19, 2023 | finance.yahoo.com
Lisata Therapeutics, Inc. (NASDAQ:LSTA) Q2 2023 Earnings Call Transcript
August 16, 2023 | finance.yahoo.com
Q2 2023 Lisata Therapeutics Inc Earnings Call
August 15, 2023 | finanznachrichten.de
Lisata Therapeutics, Inc.: Lisata Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
August 15, 2023 | finance.yahoo.com
Impilo Therapeutics Launches to Enable Nucleic Acid-Based Medicines to Effectively Treat Solid Tumor Cancers
August 14, 2023 | msn.com
Lisata Therapeutics GAAP EPS of -$0.50 beats by $0.20
See More Headlines
Receive LSTA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lisata Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/02/2023
Today
12/11/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
4/04/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:LSTA
CUSIP
N/A
CIK
320017
Web
www.caladrius.com
Phone
(908) 842-0100
Fax
646-514-7787
Employees
27
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$15.00
High Stock Price Target
$15.00
Low Stock Price Target
$15.00
Potential Upside/Downside
+476.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($2.68)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-54,220,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-36.16%
Return on Assets
-33.05%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
11.15
Quick Ratio
11.15

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$8.44 per share
Price / Book
0.31

Miscellaneous

Outstanding Shares
8,139,000
Free Float
6,381,000
Market Cap
$21.16 million
Optionable
Not Optionable
Beta
1.13
12 Stocks Corporate Insiders are Abandoning Cover
12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Dr. David J. Mazzo B.A. (Hons) (Age 66)
    B.Sc. (Hons.), M.Sc., Ph.D., President, CEO & Director
    Comp: $1.16M
  • Dr. Kristen K. Buck M.D. (Age 49)
    Executive VP of R&D and Chief Medical Officer
    Comp: $938.42k
  • Mr. James Nisco
    VP of Finance & Treasury
  • Mr. Tariq Imam
    Vice President of Business Development & Operations and Corporate Counsel
  • Mr. Gregory S. Berkin
    Chief Information Officer
  • Mr. John D. Menditto
    Vice President of Investor Relations & Corporate Communications
  • Ms. Gail Holler (Age 64)
    Vice President of Human Resources
  • Dr. William K. Sietsema Ph.D. (Age 67)
    Vice President of Global Regulatory Affairs
    Comp: $350.55k

Key Competitors

View All Competitors














LSTA Stock Analysis - Frequently Asked Questions

Should I buy or sell Lisata Therapeutics stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Lisata Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" LSTA shares.
View LSTA analyst ratings or view top-rated stocks.

What is Lisata Therapeutics' stock price target for 2024?

1 Wall Street analysts have issued 12 month target prices for Lisata Therapeutics' stock. Their LSTA share price targets range from $15.00 to $15.00. On average, they anticipate the company's share price to reach $15.00 in the next year. This suggests a possible upside of 474.7% from the stock's current price.
View analysts price targets for LSTA or view top-rated stocks among Wall Street analysts.

How have LSTA shares performed in 2023?

Lisata Therapeutics' stock was trading at $2.53 at the start of the year. Since then, LSTA stock has increased by 3.2% and is now trading at $2.61.
View the best growth stocks for 2023 here.

When is Lisata Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 4th 2024.
View our LSTA earnings forecast.

How were Lisata Therapeutics' earnings last quarter?

Lisata Therapeutics, Inc. (NASDAQ:LSTA) issued its quarterly earnings data on Thursday, November, 2nd. The company reported ($0.65) earnings per share for the quarter, topping analysts' consensus estimates of ($0.93) by $0.28.

Who are Lisata Therapeutics' major shareholders?

Lisata Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%).

How do I buy shares of Lisata Therapeutics?

Shares of LSTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:LSTA) was last updated on 12/11/2023 by MarketBeat.com Staff

My Account -